The world’s first “M3 bacterial genetic testing technology” represents more than ten years of scientific research and was developed by the Faculty of Medicine of a renowned university in Hong Kong.
 
 
Non-invasive, patented detection of M3 bacteria associated with colorectal cancer, providing three risk assessments.
 
 
Monitors colorectal polyps of different sizes, as well as polyp recurrence.
 
 
Awarded the Silver Medal at the 2022 International Exhibition of Inventions Geneva.
 
 
Non-invasive, painless and easy to use with stool sample collection.

G-NiiB gniib M3CRC is the world’s first innovative scientific technology of its kind. It is the only non-invasive colorectal cancer risk test currently available on the market that can detect colorectal polyps of different sizes. Its sensitivity for detecting colorectal cancer is up to 94%, which is comparable to colonoscopy.